<DOC>
	<DOCNO>NCT00005077</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness oxaliplatin treat patient advanced cancer plus liver dysfunction .</brief_summary>
	<brief_title>Oxaliplatin Treating Patients With Advanced Cancer Plus Liver Dysfunction</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose oxaliplatin patient advanced malignancy vary degree liver dysfunction . II . Determine effect hepatic dysfunction plasma pharmacokinetics pharmacodynamics oxaliplatin patient . OUTLINE : This dose escalation , multicenter study . Patients stratify accord liver function define follow : Group A : Normal liver function - Bilirubin , SGOT , alkaline phosphatase great upper limit normal ( ULN ) Group B : Mild liver dysfunction - Bilirubin great ULN ; SGOT great ULN 2.5 time ULN and/or alkaline phosphatase great ULN 5 time ULN Group C : Moderate liver function - Bilirubin great ULN 3.0 mg/dL and/or SGOT great 2.5 time ULN and/or alkaline phosphatase great 5 time normal Group D : Severe liver dysfunction - Bilirubin great 3.1 mg/dL SGOT alkaline phosphatase Group E : Patients receive liver transplant Patients receive oxaliplatin IV 2 hour day 1 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient group B , C , D receive escalate dos oxaliplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose- limiting toxicity . PROJECTED ACCRUAL : Approximately 72 patient accrue study within 1.5 year .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic unresectable malignancy curative palliative treatment exist No brain metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : At least 2 month Hematopoietic : Platelet count least 100,000/mm3 WBC least 3,000/mm3 OR Absolute neutrophil count least 1,500/mm3 Hepatic : Abnormal liver function allow Renal : Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other : No clinically significant neuropathy Not pregnant nursing Fertile patient must use effective contraception No history allergy platinum compound antiemetic may use study No uncontrolled concurrent illness ( e.g. , ongoing active infection ) PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent colony stimulate factor first course study Chemotherapy : No 3 prior regimen chemotherapy At least 6 week since prior platinum chemotherapy At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy 30 % bone marrow Surgery : At least 10 day since placement biliary shunt Other : No concurrent investigational agent No concurrent antiretroviral therapy ( HAART ) HIV positive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>